# US 10,307,361 B2 · Vesicles containing saccharide isomerate, hydrolyzed lupine protein, and intercorneocyte lipid mimetics as active ingredient, and composition for skin external application comprising the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,307,361 B2
- Document ID: US10307361B2
- Status: Granted
- Kind: B2
- Application number: 15/820,093
- Filed: 2017-11-21
- Published: 2018-05-24
- Granted: 2019-06-04
- Earliest claimed: 2016-11-22
- Assignees: Cms Lab Inc.
- Applicants: CMS LAB Inc.
- Inventors: Min-Hye Lee; Young-Chul Ko; Kang-Min Yoo; Seung-ki Hong; Jin-Soo Lee
- Web page: https://patentgrep.com/patent/US10307361B2

## CPC

- A61K 8/645: {Proteins of vegetable origin; Derivatives or degradation products thereof}
- A61K 8/14: Liposomes; Vesicles
- A61K 8/345: {containing more than one hydroxy group}
- A61K 8/361: {Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof}
- A61K 8/375: {the alcohol moiety containing more than one hydroxy group}
- A61K 8/553: {Phospholipids, e.g. lecithin}
- A61K 8/60: Sugars; Derivatives thereof
- A61K 8/63: Steroids; Derivatives thereof
- A61K 8/68: Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
- A61K 8/73: Polysaccharides
- A61K 8/9789: Magnoliopsida [dicotyledons]
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/007: {Preparations for dry skin}
- A61K 2800/78: Enzyme modulators, e.g. Enzyme agonists
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to a vesicle containing a saccharide isomerate, a hydrolyzed lupine protein, and an intercorneocyte lipid mimetics as an active ingredient, and a composition for skin external application including the vesicle, and more particularly, to a vesicle including: an aqueous phase part including a saccharide isomerate and a hydrolyzed lupine protein; and an oil phase part including an intercorneocyte lipid mimetics, lysolecithin, and glycerin. The vesicle includes the intercorneocyte lipid mimetics together with the saccharide isomerate and the hydrolyzed lupine protein as contents, so that the vesicle is excellent in a skin barrier recovery function and a skin moisturizing effect upon skin application. In addition, the vesicle is excellent in phase stability, so that the vesicle is suitable to be commercialized as various compositions for skin external application.

## Claims

### Claim 1

A vesicle containing a saccharide isomerate, a hydrolyzed lupine protein, and an intercorneocyte lipid mimetics as an active ingredient, the vesicle comprising:
an oil phase part obtained by dispersing 10 wt % to 75 wt % of the intercorneocyte lipid mimetics and 1 wt % to 10 wt % of lysolecithin in 1 wt % to 20 wt % of glycerin; and
an aqueous phase part obtained by dissolving 0.01 wt % to 7 wt % of the saccharide isomerate and 0.01 wt % to 7 wt % of the hydrolyzed lupine protein in the balance of purified water,
wherein the intercorneocyte lipid mimetics includes 10 wt % to 70 wt % of an intercorneocyte lipid component, 0.1 wt % to 20 wt % of an amphoteric surfactant, 2 wt % to 20 wt % of saturated lecithin, 5 wt % to 20 wt % of glycerin, and the balance of purified water based on a total weight of the intercorneocyte lipid mimetics.

### Claim 2 (depends on 1)

The vesicle of claim 1, wherein the intercorneocyte lipid component includes 5 wt % to 60 wt % of ceramide, 5 wt % to 35 wt % of a cholesterol derivative containing cholesterol or a phytosterol derivative containing phytosterol, and 5 wt % to 60 wt % of a higher fatty acid based on a total weight of the intercorneocyte lipid component.

### Claim 3 (depends on 2)

The vesicle of claim 2, wherein the higher fatty acid is obtained by mixing palmitic acid:stearic acid: oleic acid:linolenic acid in a weight ratio of 1 to 5:1 to 10:1 to 6:1 to 4.

### Claim 4 (depends on 1)

The vesicle of claim 1, wherein the vesicle enhances a skin barrier function and a skin moisturizing effect by increasing expression of filaggrin, laminin-5, and type-4 collagen.

### Claim 5 (depends on 1)

A composition for skin external application comprising the vesicle containing the saccharide isomerate, the hydrolyzed lupine protein, and the intercorneocyte lipid mimetics as the active ingredient according to claim 1.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the composition comprises one type of formulation selected from the group consisting of a liquid, a suspension, an emulsion, a gel, a cream, an ointment, a spray, and a paste.